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Abstract
Background
Diagnosis of inflammatory bowel disease (IBD) in primary care (PC) is challenging and
associated with a considerable diagnostic delay. Using a calprotectin test for any PC patient
with abdominal complaints would cause significant costs. The 8-item-questionnaire Calpro-
Quest was developed to increase the pre-test probability for a positive Calprotectin. It is a
feasible instrument to assess IBD in PC, but has not yet been evaluated in clinical routine.
This study, therefore, aimed to validate whether the CalproQuest increases pretest-proba-
bility for a positive fecal Calprotectin.
Methods
Prospective diagnostic trial. The CalproQuest consists of 4 major and 4 minor questions
suggestive for IBD. It is considered positive if� 2 major or 1 major and 2 minor criteria are
positive. Primary outcome: Sensitivity and specificity of the CalproQuest for Calprotectin lev-
els� 50 μg/g and for positive IBD diagnosis among patients referred to endoscopic evalua-
tion at secondary care level. Secondary finding: Patient-reported diagnostic delay.
Results
156 patients from 7 study centers had a complete CalproQuest and fecal Calprotectin test.
The sensitivity and specificity of CalproQuest for Calprotectin� 50 μg/g was 36% and 57%.
The sensitivity and specificity of the CalproQuest for positive IBD diagnosis was 37% and
67%. The diagnostic delay was 61 months (SD 125.2).
Conclusion
In this prospective diagnostic study, the sensitivity and specificity of CalproQuest for Calpro-
tectin levels� 50 μg/g and positive IBD diagnosis were poor. Additional prospective studies
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concerning the ideal cut-off values, validity and cost-effectiveness of a combined use with
the Calprotectin test in the PC setting are necessary.
Introduction
The estimated prevalence of inflammatory bowel disease (IBD), consisting of Crohn’s Dis-
ease (CD), ulcerative colitis (UC) and indeterminate colitis (IC) [1], is 0.2% in the western
world [2]. Hence, it is not surprising that physicians are often faced with the diagnostic chal-
lenge to differentiate patients with IBD from functional gastrointestinal disorders, namely
irritable bowel syndrome (IBS), based on its much higher prevalence estimated at 10–15%
[3]. These challenges are reflected in the considerable diagnostic delay of IBD [1], associated
with a significantly increased risk of morbidity and mortality [4]. Although IBS-like symp-
toms are frequently reported in patients before IBD is diagnosed [5], it is not useful that
every patient undergoes an invasive endoscopic examination. As an intermediary diagnostic
approach the fecal Calprotectin has been shown to reflect intestinal inflammation in
patients with known IBD [6–12] and to differentiate IBD from IBS, depending on the cut-off
value used. [13–16] Nevertheless, the Calprotectin test is not routinely performed in
primary care (PC). The pre-test probability would be very low if a Calprotectin test would be
used in all patients with abdominal complaints [17, 18]. A further problem is the low
specificity of the test (many possible differential diagnoses for a positive Calprotectin test
besides IBD such as esophagitis, gastritis, gastric ulcers, celiac disease, benign or malignant
polyps and cancer, infectious gastroenteritis/colitis, diverticulitis, microscopic and ischemic
colitis, NSAR enteropathy, lactose intolerance) and relatively high costs (currently about 60
Euros). Systematic data regarding the use of fecal Calprotectin test especially in PC are
lacking.
To increase pretest-probability for a positive test result of the fecal Calprotectin test aiming
at diagnosing IBD in an earlier stage, we developed an 8-item-questionnaire: the CalproQuest
[19]. The CalproQuest has been shown to be a feasible instrument for the assessment of IBD in
PC, but has not yet been evaluated clinically [20]. This study aims to prospectively validate the
CalproQuest concerning sensitivity and specificity for positive fecal Calprotectin test results
and positive IBD diagnosis.
Materials and methods
Ethics, trial registration, informed consent
• Ethics: The study protocol was approved by the Ethics Committee of the Kanton Zurich (ref-
erence KEK-ZH-number 2013–0516).
• The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as
reflected in a prior approval by the institution’s human research committee.
• Trial registration number: ISRCTN66310845.
• Written informed consent was obtained from each patient included in the study.
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Study design
This study is a part of the prospective diagnostic ALERT trial (VAlidation of an 8-item-ques-
tionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in primary
care to reduce diagnostic delay in IBD), consisting of two independent parts A and B, con-
ducted by gastroenterologists (GEs) (A) and general practitioners (GPs) (B). The details of
the study design, including recruitment of patients and physicians, administration of patient
records, informed consent, confidentiality have been published previously [19]. In part B of
the ALERT Trial, the CalproQuest has been shown to be a feasible instrument for the assess-
ment of IBD in PC [20]. Patients included in the current study were referred to GEs for endo-
scopic evaluation with any indication. The study design including the study flow is depicted
in Fig 1.
Inclusion and exclusion criteria
Inclusion criteria:
• �18 years
• Referral to GE for colonoscopy with any indication
• Informed consent
Exclusion criteria:
• Known abdominal pathologies besides known IBD, e.g. cancer
Procedure (see also Fig 1)
• Patients referred to the GE for colonoscopy due to any reason were included into the study
(besides in- and exclusion criteria)
• Patients were subjected to CalproQuest prior to endoscopy
• Patients obtained fecal samples to measure Calprotectin levels
• Colonoscopy was performed to obtain diagnosis
• Patients with an IBD diagnosis were asked to complete a questionnaire investigating dura-
tion of first onset of symptoms to IBD diagnosis (diagnostic delay)
CalproQuest
CalproQuest is an 8-item IBD-questionnaire consisting of 4 major and 4 minor questions sug-
gestive for IBD (Table 1). The CalproQuest has been shown to be a feasible instrument for the
assessment of IBD in PC [20]. The original questionnaire used in our study (German language)
can be seen in supporting information (S1 File). The CalproQuest is considered positive, if� 2
major criteria or 1 major criterion and 2 minor criteria are answered positively. We assumed
that a positive CalproQuest result might predict calprotectin levels� 50 μg/g. Calprotectin lev-
els above 50 μg/g are indicative for active intestinal inflammation and call for further endo-
scopic examination.
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Fecal calprotectin
Fecal calprotectin levels were measured at the University Hospital Zurich. Specimens from
other study centers were sent to the laboratory by mail. The Calprotectin test is called EliA Cal-
protectin (Thermo Fisher Scientific, Uppsala, Sweden) and uses the FEIA method (fluores-
cence enzyme immunoassay) on a fully automated system called Phadia 100 (Thermo Fisher
Scientific, Uppsala, Sweden). The EliA Calprotectin Wells are coated with monoclonal
Fig 1. Study flow Feasibulity of CalproQuest. Neg = negative; Pos = positive; IBD = Inflammatory bowel disease.
https://doi.org/10.1371/journal.pone.0224961.g001
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antibodies to calprotectin. If present in the patient’s specimen, calprotectin binds to the coated
antibodies. After washing away non-bound components, enzyme-labeled antibodies against
human calprotectin (EliACalprotectin Conjugate) are added to form a calprotectin-conjugate
complex. After incubation, non-bound conjugate is washed away and the bound complex is
incubated with a Development Solution. After stopping the reaction, the fluorescence in the
reaction mixture is measured. The higher the response value, the more calprotectin is present
in the specimen. To evaluate test results, the response for patient samples is compared directly
to the response for calibrators.
Diagnostic delay
Three time intervals of diagnostic delay were assessed retrospectively in a patient questionnaire
(S2 File in German language): Interval 1: Time from first IBD-related symptoms to first con-
sultation with a physician. Interval 2: Time from the first physician visit to referral to GE:
Interval 3: Time from first IBD symptoms to IBD diagnosis (interval 1+2): This interval is
defined as diagnostic delay and describes time span from first symptoms to IBD diagnosis.
Primary and secondary outcomes
Primary outcomes:
• Sensitivity and specificity of CalproQuest for a positive Calprotectin test result� 50 μg/g
feces
• Sensitivity and specificity of CalproQuest for a positive Calprotectin test result� 50 μg/g
feces and positive IBD-diagnosis.
Secondary finding:
• Patient-reported diagnostic delay
Statistical analysis
A data set was considered complete if a patient completed both the CalproQuest and the Cal-
protectin test. The sensitivity and specificity calculation of CalproQuest is based on confidence
intervals. P<0.05 is considered statistically significant. The sample size was calculated accord-
ing to Flahault et al. [21]. Assuming a 0.05 two-sided significance level, n = 162 would have
90% power to detect a sensitivity and specificity of 90% of CalproQuest for a calprotectin
level� 50 μg/g feces, or for a calprotectin level� 50 μg/g feces and a positive IBD diagnosis.
For the purpose of this calculation, the expected sensitivity and specificity are 90% with a
Table 1. CalproQuest (8-item inflammatory bowel disease questionnaire).
Type Criteria Yes
(1)
No
(0)
Comment
Major Does the patient suffer from abdominal pain at least 3 times a week for at least 4 weeks?
Does the patient suffer from diarrhea (more than 3 bowel movements daily) for 7 consecutive days?
Does the patient have diarrhea at night-time/Does the patient awake from sleep because of abdominal pain or diarrhea?
Does the patient report bloody stool?
Minor Does the patient report mucus in stool for more than 4 weeks?
Does the patient report unwanted weight loss (5% of normal body weight over 6 months)?
Does the patient present with fever or report fever over the last 4 weeks (Temperature> 38˚C)?
Does the patient report fatigue over the last 4 weeks?
https://doi.org/10.1371/journal.pone.0224961.t001
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lower acceptable limit of sensitivity of 70%. Assumed prevalence of IBD within the sample was
20%. A p<0.05 is considered statistically significant. Statistical analysis was performed with R
(R version 3.3.2) [22].
Results
Population
Recruitment of GEs started in October 2014 and ended after completion of the necessary data-
set in January 2017. Recruitment was undertaken by means of information events as well as
mailings and personal contacts of the involved team. Therefore, no actual non-responder list
was compiled. The study flow can be appreciated in Fig 1.
From the 191 eligible patients in 7 study centers, 188 remained for analysis meeting the
inclusion and exclusion criteria, 156 had a complete CalproQuest as well as a Calprotectin test
(Fig 1 and Table 2). The centers recruited between 3 and 19 patients. The details of the study
population are listed in Table 2. 150 endoscopic results were available for analysis, of which 80
hat an IBD diagnosis (54 active, 24 in remission). 21 endoscopies showed other diagnoses (e.g.
diverticulitis, diverticulosis, etc.). 49 endoscopies showed no pathological findings.
Primary outcome: Validation of CalproQuest
The sensitivity and specificity of CalproQuest for fecal Calprotectin levels� 50 μg/g was 36%
and 57% (n = 156). Positive IBD diagnosis was defined as endoscopic diagnosis of active CD
or UC or IC (n = 54). The sensitivity and specificity of the CalproQuest for positive IBD diag-
nosis was 37% and 67% (Fig 2).
Fig 3 shows the sensitivity and specificity of CalproQuest depending on different Calprotec-
tin levels and on whether the diagnosis of IBD was assessed in a first or follow up endoscopy.
Secondary finding: Patient-reported diagnostic delay
The mean time from first IBD related symptoms to first consultation with a physician (Interval
1) was 6 months (SD 16.3). The mean reported time from the first physician visit to referral to
a gastroenterologist (Interval 2) was 19 months (SD 58.6). The diagnostic delay (= time from
first IBD symptoms to IBD diagnosis (Interval 3 = Interval 1+2)) was 61 months (SD 125.2).
Discussion
In this prospective diagnostic study, the sensitivity and specificity of CalproQuest, an 8-item
IBD-questionnaire consisting of 4 major and 4 minor questions, for fecal Calprotectin
levels� 50 μg/g as well as positive IBD diagnosis were poor.
The CalproQuest has been shown to be a feasible instrument for the assessment of IBD in
PC care [20]. In the current prospective diagnostic study, the CalproQuest is for the first time
evaluated clinically. The question arises why the results turned out poor. In current literature,
very few studies exist evaluating the use of questionnaires to aid GP’s ruling out IBD, hence it
is difficult to compare our results. Danese et al. [23] published a 21-item questionnaire, which
was developed by means of a systematic literature review in which CD specialists identified
“red flags”, i.e. symptoms or signs suggestive of CD. However, this questionnaire was not yet
tested for feasibility in PC and has not yet been prospectively validated. As Holtman et al. [24]
have stated correctly, low prevalence of IBD and lack of uniform reference standards in PC
induce methodological challenges to investigate the diagnostic accuracy of a test. In Switzer-
land only about 7% of patients consult their GP due to gastrointestinal complaints [25], of
which only a minority (0.2%) is diagnosed with IBD [2], whereas the prevalence of IBS is
Can the CalproQuest predict a positive Calprotectin test? A prospective diagnostic study
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estimated at 10–15% [3]. In order to achieve the necessary power to estimate the sensitivity
and specifity of the CalproQuest in the PC setting, more than 2000 patients would have had to
be recruited, due to the low prevalence of gastrointestinal complaints in PC. In the current
study, we therefore decided to estimate the diagnostic performance of the CalproQuest at sec-
ondary care, i.e. among the GEs. By recruiting 156 patients with a complete data set (complete
Table 2. Baseline characteristics of the study population.
level frequency percent
CalproQuest (n = 156) negative 94 60.3
positive 62 39.7
Sex (n = 155) female 75 48.4
male 80 51.6
First endoscopy (n = 150) No 86 57.3
yes 64 42.7
Follow up endoscopy (n = 150) No 64 42.7
yes 86 57.3
Active Crohn’s disease (n = 150) No 126 84
yes 24 16
Active colitis ulcerosa (n = 150) 0 126 84
1 24 16
Active indeterminate inflammatory bowel disease (n = 150) 0 144 96
1 6 4
Active inflammatory bowel disease (Crohn’s or colitis ulcerosa or indeterminate) (n = 150) 0 96 64
1 54 36
Crohn in remission (n = 150) 0 137 91.3
1 13 8.7
Colitis ulcerosa in remission (n = 150) 0 137 91.3
1 13 8.7
Other diagnoses (n = 150) Diverticulitis 2 2.9
Diverticulosis 6 8.6
Diverticulosis and polyp 3 4.3
Hemorrhoids 2 2.9
Microscopic colitis 2 2.9
No findings 49 70
Polyp 6 8.6
Medication (n = 132) O 71 59.7
C 2 1.7
C, O 7 5.9
C, N 1 0.8
C, N, O 2 1.7
N 2 1.7
N, O 10 8.4
S 3 2.5
S, O 15 12.6
S, C, O 3 2.5
S, C, N, O 1 0.8
S, N, O 2 1.7
n = available data, C = contraceptives, N = non-steroidal anti-inflammatory rheumatics, S = steroids, O = other.
https://doi.org/10.1371/journal.pone.0224961.t002
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CalproQuest and Calprotectin), we nearly achieved the targeted number of 163 patients, based
on the power calculation. Taking into consideration that the active IBD prevalence in our
study population was 34.6%, i.e. substantially higher than the 20% as estimated in the power
calculation [19], the power was actually more than achieved. The mediocre diagnostic accuracy
of the CalproQuest for a positive Calprotectin therefore represents a true finding and cannot
be explained by the study design. A possible explanation for the poor results might lie in the
diagnostic accuracy of the fecal calprotectin test itself and the low cut-off value of 50 μg/g cho-
sen in our study. Although testing for fecal calprotectin has been shown to be a helpful diag-
nostic tool for IBD in tertiary care and especially as a follow-up parameter (13–16), it remains
unclear whether its widespread use for diagnostic rather than follow-up purposes in primary
and secondary care is appropriate. The fecal calprotectin test was not validated in the low prev-
alence setting of PC [26] and has diverse differential diagnoses for a positive result besides
IBD, which renders its utility even more unclear in a low prevalence setting. Recently pub-
lished studies in the PC setting have shown a doubtful benefit of the calprotectin test in
diagnosing IBD in PC [27], whereas other non-invasive markers, such as the fecal immuno-
chemical test (FIT), showed far better results in detecting colorectal cancer, high-risk adeno-
mas and IBD [28], [29]. Also in the pediatric PC setting recent findings indicate that the fecal
calprotectin test may not be as helpful as assumed from specialist care: A positive fecal
Fig 2. Sensitivity, Specifity and predictive values of the CalproQuest. TP = true positive, TN = true negative,
FP = false positive, FN = false negative, PPV = Positive Predictive Value = TP/(TP+FP), NPV = Negative Predictive
Value = TN/(FN+TN), Sensitivity = TP/ (TP+FN), Specificity = TN/(FP+TN), IBD = Inflammatory bowel disease.
https://doi.org/10.1371/journal.pone.0224961.g002
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calprotectin result in children with chronic gastrointestinal symptoms was not likely to be
indicative of IBD [30]. It seems reasonable that the cut-off value has to be reconsidered for this
low prevalence setting, in order to increase utility of a positive calprotectin test (positive pre-
dictive value) [27], as suggested in studies among patients with an intermediate raised fecal cal-
protectin in a ‘real-world’ setting [31–33]. A negative calprotectin tests seems to have certain
utility in ruling out IBD in PC [34, 35]. In addition, the questionable cost-effectiveness of a
widespread use in a patient population with unspecific complaints has to be taken into
consideration.
Strengths and limitations
A clear strength of this study is its clinical relevance: as a secondary finding, the diagnostic
delay was confirmed to be substantial and hence comparable with previous studies. [1, 4] Since
this substantial diagnostic delay is clearly associated with an increased risk of morbidity and
mortality [4], studies like this one tackling the issue how to timely diagnose these patients are
of utmost importance.
Fig 3. Sensitivity and Specificity of the CalproQuest depending on Calprotectin levels and on first or follow up endoscopy. No association was
found between the sensitivity and specifity of the CalproQuest with different Calprotectin levels or with the endoscopy being performed for the first
time or as a follow up endoscopy.
https://doi.org/10.1371/journal.pone.0224961.g003
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Certain limitations have to be taken into consideration: As mentioned above, in order to
achieve the necessary power to estimate sensitivity and specificity of the CalproQuest in the
GP setting, more than 2000 patients would have had to be recruited, due to this low prevalence
of gastrointestinal complaints in PC. In the current study, we therefore chose to estimate the
diagnostic performance of the CalproQuest at secondary care level, i.e. among GEs. In addi-
tion, there is evidence for great variability in the concentrations of calprotectin in stool samples
collected during a single day with increasing variability of concentrations in longer storage
periods [36]. Since our study protocol did not predefine a specific storage time, our study
results could have been negatively influenced. Since 15% the patients in the study took non-
steroidal anti rheumatics, which are known to increase fecal Calprotectin levels, our findings
could have been influenced [37]. Since the exact and cumulative dosages of medication intake
was not known, further sub-analyses are not possible to correct for this confounding element.
In summary, the poor predictive power for the CalproQuest might possibly be improved to
reach a major diagnostic power by means of the following measures: more specific instructions
concerning stool sampling procedure, especially concerning storage time, the use of another
potentially better fecal test, than the Calprotectin, such as the fecal immunochemical test
(FIT), the use of a higher cut of level of the Calprotectin, and finally testing in the PC rather
the secondary care setting with a larger sample size.
Conclusion
In this prospective diagnostic study, the sensitivity and specificity of CalproQuest for fecal Cal-
protectin levels� 50 μg/g as well as positive IBD diagnosis were poor. Additional prospective
studies concerning the ideal cut-off values, validity and cost-effectiveness of a combined use
with the Calprotectin test in the PC setting are necessary.
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